Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference13 articles.
1. Smith MY, van Til J, DiSantostefano RL, Hauber AB, Marsh K. Quantitative benefit–risk assessment: state of the practice within industry. Therap Innovat Regulat Sci. 2021;55:415–25.
2. FDA Review of Rivaroxaban for Symptomatic PAD. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/202439Orig1s035.pdf . Accessed August 3, 2023.
3. FDA Draft Guidance on Benefit-Risk Assessment for New Drug and Biological Products. Available at https://www.fda.gov/media/152544/download . Accessed August 3, 2023
4. Marsh K, Ijzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making–emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19:125–37.
5. Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value trade-offs. Cambridge, England: Cambridge University Press; 1993.